LTRN 240920 5.00C (LTRN240920C5000) Stock Options, News & Quotes

0.35
+0.15+75.00%

15min DelayClose Aug 23 16:00 ET

0.35High0.35Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Aug 7 10:00

NEWS

$Lantern Pharma (LTRN.US)$
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-18...

Stock Region

Aug 5 18:13

Healthcare Technology Company Announces Positive Clinical Update From Cancer Trial

Lantern Pharma Announces Positive Clinical Update from Phase 2 HARMONIC™ Clinical Trial.
Lantern Pharma, a company specializing in the use of artificial intelligence (AI) for the development of cancer therapies, has recently shared promising preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. This study focuses on never smokers with advanced NSCLC, specifically lung adenocarcinoma, who have devel...

Jaguar8

Jul 10 07:34

NEWS

$Lantern Pharma (LTRN.US)$
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...

Jaguar8

Jun 12 07:12

NEWS

$Lantern Pharma (LTRN.US)$
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

jimmy the trader

May 9 08:46

Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration

Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration $Lantern Pharma (LTRN.US)$

Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration